The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective.

Lewis, Lavinia M; Badkar, Advait V; Cirelli, David; Combs, Rodney; Lerch, Thomas F

Lewis, Lavinia M; Badkar, Advait V; Cirelli, David; Combs, Rodney; Lerch, Thomas F.

Afiliação

Lewis LM; BioTherapeutics Pharmaceutical Sciences, Pfizer Inc, Chesterfield, MO, USA. Electronic address: lavinia.m.lewis@pfizer.com.
Badkar AV; BioTherapeutics Pharmaceutical Sciences, Pfizer Inc, Andover, MA, USA.
Cirelli D; BioTherapeutics Pharmaceutical Sciences, Pfizer Inc, Andover, MA, USA.
Combs R; BioTherapeutics Pharmaceutical Sciences, Pfizer Inc, Chesterfield, MO, USA.
Lerch TF; BioTherapeutics Pharmaceutical Sciences, Pfizer Inc, Chesterfield, MO, USA.

J Pharm Sci ; 112(3): 640-647, 2023 03.

Article em En | MEDLINE | ID: mdl-36130677

Assuntos

Vacinas contra COVID-19; COVID-19; Humanos; Vacina BNT162; COVID-19/epidemiologia; COVID-19/prevenção & controle; RNA Mensageiro; Preparações Farmacêuticas

Palavras-chave

Global Health; Lipid Nanoparticles; Vaccine; Vaccine delivery; mRNA

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: J Pharm Sci Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google